Trial
NCT06516887
Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
National Cancer Institute (NCI)
Condition
Advanced Lung Adenocarcinoma
Intervention
bemcentinib
Why stopped
Investigational drug limitations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-26